glp-1 drug exposure pharmaceutical companies 2025 Trends: Costs & Coverage Barrier Amid Uncertainty SUSTAINABLE GLP-1 DRUG DELIVERY: FUTURE-PROOFING
Description
Incretin-based drugs and renoprotection-is hyperfiltration key
Meanwhile, individuals who took a high-potency GLP-1 drug approved for obesity - such as semaglutide - had greater persistence at 14% three years after initiating therapy
And topiramate seems to have similar effects as the FDA-approved drugs but has a lot more adverse events
In other words, if youve been prescribing compounded versions of Tirzepatide, its time to start looking at the commercially available products again or prescribe a compounded alternative
Turner DS, Etheridge L, Jones J, Marks V, Meldrum B, Bloom SR, et al
